![](https://webarchive.library.unt.edu/eot2008/20090115053818im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090115053818im_/http://www.cancer.gov/images/spacer.gif)
yttrium Y 90 anti-CD19 monoclonal antibody BU12 A radioimmunoconjugate consisting of the murine IgG1 anti-CD19 monoclonal antibody (MoAb) BU12 labeled with the beta-emitting radioisotope yttrium Y 90 with radioisotopic and antibody activities. Yttrium Y 90 anti-CD19 monoclonal antibody BU12 binds to the CD19 molecule, specifically delivering cytotoxic beta radiation to CD19-expressing B cells. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090115053818im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115053818im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115053818im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115053818im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090115053818im_/http://www.cancer.gov/images/spacer.gif) |